News
We send the latest information from SMC Laboratories.
Genfit announced that it will discontinue the Phase 3 NASH study and concentrate on the developmento of PBC therapeutics.
Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical …
Merck's publication in Cell Reports Medicine
SMC announces that Merck & Co., Inc. (NJ) has published the results of a study using STAMTM mouse model in…
DURECT has published a news release regarding positive topline data from phase 1b study of DUR-928 in NASH
DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enz…
FDA rejects Intercept Pharma's drug for NASH for now
Intercept Pharmaceuticals, Inc. (USA) announced that it has received a notification from the FDA that it will …
Hepion pharma has publshed a pres releaes regarding the CRV431 efficacy evaluation study for kidney fibrosis we have provied.
Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model. &…
Continuum Biosciences’s publication in Journal of Medicinal Chemistry
SMC announces that Continuum Biosciences, Pty Ltd. has published the results of a study using STAM model on Jo…
Sabinsa Corporation’s publication in Scientific Reports
SMC announces that Sabinsa Corporation has published the results of a study using STAM model in Scientific Rep…
Juntendo University’s publication on European Radiology Experimental
SMC announces that Juntendo University has published the results of a study using STAM™ model in Europea…
Genomics Institute of the Novartis Research Foundation’s publication on Journal of Medicinal Chemistry
SMC announces that Genomics Institute of the Novartis Research Foundation has published the results of a study…
Can-Fite BioPharma’s publication on International Journal of Molecular Medicine
SMC announces that Can-Fite BioPharma has published the results of a study using STAM™ model in Internat…